• MedinCell
    • Who we are
    • What we do
    • Responsibility
  • Product
    • Pipeline
    • Opportunities
    • Scale-up
  • LAI
    • Impact
    • Technology
    • Flexibility
    • MC Fluidics
  • Network
    • Partners
  • News
  • Careers
MedinCell MedinCell MedinCell MedinCell
  • MedinCell
    • Who we are
    • What we do
    • Responsibility
  • Product
    • Pipeline
    • Opportunities
    • Scale-up
  • LAI
    • Impact
    • Technology
    • Flexibility
    • MC Fluidics
  • Network
    • Partners
  • News
  • Careers
  • Product portfolio
    & LAI opportunities


Product pipeline
Last update: March 2018

3 products in development

mdc-IRM  
Phase III

Schizophrenia – subcutaneous injection

                     

mdc-CWM
Phase II

Pain and Inflammation – intra-articular injection

                     

mdc-TJK   
Preclinical

Schizophrenia – subcutaneous injection

                     

6 products in formulation research

mdc-WWM   
Formulation research

Contraception – subcutaneous injection

                     

mdc-ANG     
Formulation research

Schizophrenia – subcutaneous injection

                     

mdc-ELK       
Formulation research

Depression – subcutaneous injection

                     

mdc-CMV      
Formulation research

Anesthesia, Pain – perineural injection

                     

mdc-NVA      
Formulation research

Pain – perineural injection

                     

mdc-GRT       
Formulation research

Organ Transplant – subcutaneous injection

                     

Favorable risk assessment

All current products under development are based on already approved APIs. When compared to NCEs (New Chemical Entity), use of well-understood, approved APIs is an opportunity to make treatments quickly available with significantly less financial resources needed and less risk in clinical phases.



LAI Opportunities

Identification

We have designed a strong procedure to identify LAI opportunities and enlarge our portfolio of proprietary and partnered products. This assessment process aims to identify the unmet needs in a large panel of indications that could be met with LAI and to identify the most compatible APIs with our technology. This preliminary step is essential to increase significantly the likelihood of success for each product entering formulation stage.



Opportunities with approved APIs

Products based on already approved APIs can benefit from decreased time-to-market thanks to simplified pathways such as the 505(b)2 in the US, while providing all of the benefits from long-acting formulations with controlled release.

  

Generic API
+
Same indication

∨

Best-in-class products

Generic API
+
New indication

∨

First-in-class products

Protected API
+
Same indication

∨

Life Cycle Management

  

Opportunities with new APIs

There are a fair amount of new therapeutic molecules that could be optimized for long-acting injectable treatments. Our technology could be the empowering entity to APIs that can’t be used in today’s traditional, drug delivery systems, or whose benefits would be limited as a result of toxicity.

                     


GMP ready

Partnership with Corbion

CM Biomaterials, our joint-venture with Corbion – leading manufacturer of biomedical polymers worldwide – aims to ensure that an adequate supply of GMP (Good Manufacturing Practice) quality polymers is available for large-scale production. More about Corbion: www.corbion.com


The benefits


Fluid scale-up to large scale GMP
production

Preserved manufacturing IP

Controlled polymer quality

Say hello to BEPO®



Contact

Send

 


MedinCell

Who we are
What we do
Responsibility
Events

Product

Opportunities
Scale-up

LAI

Treatment approval
Technology
MC Fluidics

Network

Partners

Careers

Recruiting


Copyright © 2018 MedinCell. All rights reserved.        Legal        #BetterMedicine        #GlobalHealth

  • RT  @NobelPrize : The Nobel Prize has been awarded to at least 6 discoveries related to malaria. The latest was to Youyou Tu who discovered…
  • 12 hours ago

Follow @MedinCell

We use cookies to give you the best experience online! For more information, head over to our contact page and let us know what you think.Got it!Contact us